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Abstract
Background: a-Synuclein aggregates in Lewy bodies and plays a central role in the pathogenesis of a group of
neurodegenerative disorders, known as “Synucleinopathies”, including Parkinson’s disease. Parkin mutations result in
loss of parkin E3-ubiquitin ligase activity and cause autosomal recessive early onset parkinsonism.
Results: We tested how these two genes interact by examining the effects of parkin on post-translational
modification of a-Synuclein in gene transfer animal models, using a lentiviral gene delivery system into the
striatum of 2-month old male Sprague Dawley rats.
Viral expression of wild type a-Synuclein caused accumulation of a-Synuclein and was associated with increased
cell death and inflammation. a-Synuclein increased PLK2 levels and GSK-3b activity and increased the levels of
phosphorylated a-Synuclein and Tau. Parkin co-expression reduced the levels of phosphorylated a-Synuclein and
attenuated cell death and inflammation. Parkin reduced PLK2 levels and increased PP2A activation.
Conclusions: These data suggest that parkin reduces a-Synuclein levels and alters the balance between
phosphatase and kinase activities that affect the levels of phosphorylated a-Synuclein. These results indicate novel
mechanisms for parkin protection against a-Synuclein-induced toxicity in PD.
Background
Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by death of dopaminergic neurons in the
substantia nigra (SN) and accumulation of a-Synuclein
in intracellular inclusions known as Lewy bodies (LBs)
[1-10]. LBs are pathological markers of a group of dis-
eases collectively known as “Synucleinopathies”
[1,4-6,8,10]. a-Synuclein is natively unfolded and predo-
minantly non-phosphorylated in vivo [11], but in aging
human brains [12] and Synucleinopathies, a significant
fraction of aggregated a-Synuclein is phosphorylated at
Ser 129 (p-Ser 129) [11,13]. p-Ser 129 was initially
reported to accelerate the oligomerization and fibrilliza-
tion of a-Synuclein [11,14,15], as well as accumulation
and aggregation of a-Synuclein in animal models of
Synucleinopathies [16,17]. Paradoxically, recent studies
suggest that phosphorylation at Ser 129 inhibits, rather
than promotes, a-Synuclein fibrillization [18].
Parkin is an E3-ubiquitin ligase involved in proteaso-
mal degradation of proteins [19]. A loss of function
mutation in the parkin gene results in autosomal reces-
sive juvenile PD [20,21]. Specific targets of parkin E3
ubiquitin-ligase activity in vivo include an O-glycosy-
lated form of a-Synuclein, a-Synuclein P22 [22], and
Pael-R, the parkin-associated endothelin-like receptor
in vitro [23]. Parkin suppresses the toxicity of both Pael-
R in vitro [24] and mutated a-Synuclein A53T in vivo
[25,26]. Parkin deficiency in mice results in accumula-
tion of non-ubiquitinated forms of a-Synuclein in the
brain [22,23], and loss of function mutation results in
degeneration of dopaminergic neurons in transgenic
flies [27]. Although native a-Synuclein does not
appear to be a parkin substrate [28], several parkin
over-expressing animal models display protection
against a-Synuclein toxicity [25,26,29,30], suggesting a
link between the two proteins.
Parkin protects against loss of dopaminergic neurons
in the rat SN despite the increase in p-Ser 129 [25].
p-Ser 129 is ubiquitinated in LBs [31,32], suggesting
that a-Synuclein ubiquitinat i o nm a yb es e c o n d a r yt o
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i nt h ep r e s e n c eo fp a r k i na n ds y n p h i l i n - 1w h e na-
Synuclein is phosphorylated at Ser 129 [33]. To test the
potential role of parkin in modulating a-Synuclein post-
translational modifications (i.e. ubiquitination and
phosphorylation) and toxicity, we used lentiviral gene
transfer animal models, which allow us to examine the
in vivo effects of these proteins.
Methods
Cell culture, protein fractionation and Western blot
analysis
Human wild type a-synuclein cDNA, a kind gift from
Dr. Benoit Giasson, was subcloned into a tetracycline
responsive auto-regulated bi-directional expression vec-
tor, pBig2i, a kind gift of Dr. Strathdee. The immorta-
lized dopaminergic cell lines, MN9 D were stably
transfected with the pBig2isynIRESeGFP as previously
reported MN9DSYN. MN9 D cells were maintained in
Dulbecco’s modified Eagle’s medium (Sigma, D5648)
containing 10% fetal bovine serum (FBS) and hygromy-
cin B (200 μg/mL). Either MN9 D cells or M17 human
neuroblastoma cells were plated at a density of 8 × 10
4
cells/well for 12-well plates. Synuclein expression was
induced with doxycycline (2.0 μg/mL media) in MN9 D
cells 24 h prior to infection with multiplicity of infection
(m.o.i) of 100 for wild type or mutant T240R lentiviral
parkin for an additional 24 h. Human neuroblastoma
M17 cells (N = 6) 100 m.o.i of either lentiviral parkin,
T240R or LacZ were infected for 24 h. For immunopre-
cipitation and Western blot analysis, cells were har-
vested in 1× STEN buffer (50 mM Tris (pH 7.6), 150
m MN a C l ,2m ME D T A ,0 . 2 %N P - 4 0 ,0 . 2 %B S A ,2 0
mM PMSF and protease cocktail inhibitor), centrifuged
at 10,000 × g for 20 min at 4°C and the supernatant
containing the soluble fraction of a-synuclein and
parkin was collected. Cells were treated with 10 μM
okadaic acid (OA) for 3 h to inhibit phosphatases. To
extract the insoluble fraction of proteins, the pellet was
re-suspended in 4% urea and solublized for Western
blot analysis. The soluble fraction of a-synuclein was
immunoprecipitated with mouse (1:200) anti-a-synu-
clein antibody (BD Transduction Laboratories, USA)
and phospho-a-synuclein was isolated using a Phospho-
Protein Purification Kit (QIAGEN, Cat# 37101).
Generation of lentiviral constructs
To clone viral constructs used to generate animal mod-
els, cDNA templates were cloned into a lentiviral back-
bone, pLenti6/-D-TOPO (Invitrogen, CA, USA), using
Directional TOPO cloning kit. Human wild type parkin
was amplified from pcDNA3.1 plasmids (gift from Dr
Ted Dawson, Johns Hopkins University, Baltimore) by
PCR using 5’-CACC CCA TGA TAG TGT TTG TCA
GGT TC-3’ as a forward primer and 5’-GTT GTA CTT
TCT CTT CTG CGT AGT GT-3’ as a reverse primer.
Wild type a-Synuclein was amplified from pCDNA3.1
(+)-Synwt (Gift from Dr. Benoit Giasson) vector by PCR
using 5’-CAC CAT GGA TGT ATT CAT GTT TCC-3’
as a forward primer and 5’-GGC TTC AGG TTC GTA
GTC TTG AT-3’ as a reverse primer. Lentiviral con-
structs were packaged with ViraPower™ Lentiviral
Expression Systems (Invitrogen) and titrated in human
neuroblastoma M17 cells.
Stereotaxic injection
Stereotaxic surgery was performed to inject the lentiviral
constructs encoding parkin, LacZ or a-Synuclein into
the striatum of 2-month old male Sprague-Dawley rats
(total N = 16) weighing between 170-220 g as indicated
in [34]. The stereotaxic coordinates for the striatum
were 3 mm lateral, 6 mm ventral, 0.48 mm posterior.
Animals (N = 4 per group) were injected into one [35]
side of striatum with 1) a lentiviral-LacZ vector at 2 ×
10
10 m.o.i,; 2) with 1 × 10
10 m.o.i lentiviral-parkin and
1×1 0
10 m.o.i lentiviral-LacZ; 3) 1 × 10
10 m.o.i lenti-
viral-a-Synuclein and 1 × 10
10 m.o.i lentiviral-LacZ; or
4) and 1 × 10
10 m.o.i lentiviral-a-Synuclein and 1 ×
10
10 m.o.i lentiviral-parkin. Animals were euthanized
4 weeks post-injection. All animal work was approved
by Georgetown University Animal Care and Use
Committee (GUACUC), under protocol # 07-021.
Immunohistochemistry of brain sections
Immunohistochemistry was performed on 20 micron-
thick brain sections. Parkin was probed with anti-parkin
(1:200) mouse (PRK-8) monoclonal antibody (Signet
Labs, Dedham, MA). a-Synuclein was probed (1:200)
with mouse antibody (BD Transduction Laboratories,
USA), or (1:200) human specific mouse monoclonal
antibody (Thermo Fisher) followed by DAB staining.
GFAP was probed (1:200) with monoclonal antibody
(Millipore Corporation, USA), and microglia was probed
(1:200) with IBA-1 polyclonal antibody (Wako, USA).
Further staining was performed to assess neural disinte-
grative-degeneration in animal models using FD Neuro-
Silver™ staining kit II (FD NeuroTechnologies, Inc,
Baltimore, MD), which provides high contrast and rapid
silver staining for the microscopic detection of neuronal
and fiber degeneration in vivo.
Stereological methods counting were applied by a
blinded investigator using unbiased stereology analysis
(Stereologer, Systems Planning and Analysis, Chester,
MD) to determine the total positive cell counts in 20
striatal fields on at least 10 brain sections (~400 positive
cells per slide) from each animal (N = 4). An optical
fractionator sampling method was used to estimate the
total number of positive cells with multi-level sampling
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determined optically by the fractionator and cells that
fell within the counting frame were counted as the
nuclei came into view while focusing through the z-axis.
Striatal TH-positive staining was assessed by optical
density (OD) measurements. Using an Optronics
(Goleta, CA) digital camera and a constant illumination
table, digitalized images of TH immunostained striatal
sections were collected. ODs were measured using
Image-Pro Plus software (Version 3.0.1; Media Cyber-
netics, Silver Spring, MD). The OD was measured from
6 striatal coronal sections and the final reading was
calculated as an average of those values. Nonspecific
background correction in each section was done by sub-
tracting the OD value of the corpus callosum from the
striatal OD value obtained from the same section. The
OD analysis was performed under blinded condition.
Western blot analysis
Two weeks post-injection, the ipsilateral striatum was
isolated from the contralateral one and brain tissues
were homogenized in 1× STEN buffer (50 mM Tris (pH
7 . 6 ) ,1 5 0m MN a C l ,2m ME D T A ,0 . 2 %N P - 4 0 ,0 . 2 %
BSA, 20 mM PMSF and proteasec o c k t a i li n h i b i t o r ) ,
c e n t r i f u g e da t1 0 , 0 0 0×gf o r2 0m i na t4 ° Ca n dt h e
supernatant containing the soluble protein fraction was
collected. The supernatant was analyzed by Western
blot on SDS NuPAGE 4-12% Bis-Tris gel (Invitrogen).
Protein estimation was performed using BioRad protein
assay (BioRad Laboratories Inc, Hercules, CA). Parkin
was immunoprobed with (1:1000) mouse anti-parkin
(PRK8) antibody (Signet Labs, Dedham, MA) and a-
Synuclein was immunoprobed with (1:1000) mouse anti-
a-Synuclein antibody (BD Transduction Laboratories,
USA). Phospho-serine 129 (p-Ser 129) a-Synuclein was
immunoprobed (1:500) with rabbit p-Ser 129 antibody
(Affinity Bio-Reagents, USA), and p-Ser 87 was immu-
noprobed (1:100) with rabbit anti-p-Ser 87 antibody
(Gift from Dr. Hilal Lashuel, Ecole Polytechnique Feder-
ale de Lausanne, Switzerland). b-actin was probed
(1:1000) with polyclonal antibody (Cell Signaling Tech-
nology, Beverly, MA, USA). TNF-a was probed with
(1:1000) anti-TNF-a rabbit antibody (Serotec), iNOS
was probed with (1:1000) anti-iNOS rabbit antibody (BD
Transduction Laboratories, USA), and tyrosine hydroxy-
lase (TH) was probed (1:1000) with rabbit antibody
(Millipore, Temecula, CA). Total GSK-3b was probed
(1:1000) with monoclonal antibody (Biosource, Carlsbad,
CA, USA) and p-GSK-3b at tyrosine 216/279 was
probed (1:1000) with polyclonal antibody (Biosource,
Carlsbad, CA, USA), PLK-2 was probed with (1:1000)
anti-PLK2 antibody (ABNOVA). Total tau was probed
(1:1000) with tau-15 monoclonal antibody (Chemicon,
Temecula, CA, USA), and phosphorylated tau was
probed (1:1000) with epitopes against polyclonal serine-
396 (Chemicon, Temecula, CA, USA), polyclonal AT8
(1:1000) Serine-199/202 (Biosource, Carlsbad, CA, USA),
polyclonal (1:1000) serine-262 (Affinity Bio-Reagents,
USA), AT180 polyclonal (1:1000) threonine-231 (Bio-
source, Carlsbad, CA, USA), AT270 polyclonal (1:1000)
Threonine-181 (Biosource, Carlsbad, CA, USA). Phos-
phatase 2A subunits A, B and C sub-units were probed
(1:1000) with polyclonal antibodies (Thermo Scientific,
USA). Western blots were quantified by densitometry
using Quantity One 4.6.3 software (Bio Rad). At least N
= 4 was used in each group and the data was analyzed
as mean ± StDev and statistical comparison of variables
was obtained by ANOVA with Neumann Keuls multiple
comparison test, P < 0.05.
Phosphatase activity assay
To measure phosphatase activity, we used Malachite
Green Phosphate detection kit (R&D Systems) and per-
formed the assay on triplicates of striatal brain extracts
in 96-well dishes. The absorbance was read at 620 nm
according to the manufacturers’ protocols.
Caspase-3 fluorometric activity assay
To measure caspase-3 activity in the animal models, we
used EnzChek® caspase-3 assay kit #1 (Invitrogen, Mole-
cular Probes, Inc) on striatal extracts and Z-DEVD-
AMC substrate and read the absorbance was read
according to manufacturer’s protocol.
Graphs and statistics
All graphs and statistical analyses were performed in
GraphPad Prism Software (GraphPad Prism Software,
Inc. CA. USA). All statistics were performed using
ANOVA with Newman Keuls multiple comparison test
and P < 0.05 as statistically significant, N = 4 for ani-
mals and N = 6-12 for cell culture studies.
Results
Lentiviral a-Synuclein and parkin expression in gene
transfer animal models
To generate gene transfer animal models and test the
effects of human parkin and a-Synuclein in vivo,w e
injected either lentiviral parkin (Lv-Par; Figure 1A) or
a-Synuclein (Lv-Syn; Figure 1A) or LacZ (Lv-LacZ) or
both (Lv-Par + Lv-Syn) into the striatum of 2-month
old male Sprague Dawley rats. To test the effects of par-
kin on a-Synuclein, we analyzed infected striatal
extracts 4 weeks post-injection by Western blot with
parkin and a-Synuclein antibodies. As expected, the
level of parkin was significantly (ANOVA, Neumann
Keuls, P < 0.05) increased (~50%, N = 4) in animals
injected with parkin (Figure 1B &1C), and a-Synuclein
was significantly increased (41%, N = 4) in a-Synuclein
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Page 3 of 13Figure 1 A). Generation of a-Synuclein gene transfer animal models and parkin effects on total a-Synuclein levels.S c h e m a t i c
representation of lentiviral clones encoding human a-Synuclein and human wild type and mutant T240R parkin. B). Western blot analysis of
striatal brain extracts using 4-12% NuPAGE SDS gel (Invitrogen) probed with parkin (PRK8), and a-Synuclein antibodies and C). Densitometric
analysis. D). Western blot analysis of M17 cell extracts infected with T240R mutant parkin and human a-Synuclein using 4-12% NuPAGE SDS gel
(Invitrogen) probed with parkin (PRK8), and a-Synuclein antibodies. E). Parkin immnunostaining (PRK-8) of 20 micron-thick rat striatal sections
injected with E). lentiviral LacZ (Lv-LacZ), F). lentiviral parkin (Lv-Par), G). Lentiviral a-Synuclein (Lv-Syn) and H). Lentiviral parkin+lentiviral a-
Synuclein (Lv-Par+Lv-Syn). Immunoreactivity using human anti-a-Synuclein antibody followed by DAB staining in sections of rat striatum injected
with I). lentiviral LacZ, J). lentiviral parkin, K). lentiviral a-Synuclein and L). lentiviral parkin+a-Synuclein. Asterisk is significantly different to LacZ
control, ANOVA, with Neumann Keuls multiple comparison N = 4, P < 0.05.
Khandelwal et al. Molecular Neurodegeneration 2010, 5:47
http://www.molecularneurodegeneration.com/content/5/1/47
Page 4 of 13lentivirus injected brains without parkin expression.
Parkin and a-Synuclein co-expression showed increased
parkin levels, but reduced total a-Synuclein to LacZ
levels (Figure 1B &1C). Higher molecular weight bands
(>17 KD) were also observed in striatal rat brain sam-
ples. To ascertain that wild type parkin had an effect on
a-Synuclein levels, we co-infected human M17
neuroblastoma cells with mutant T240R parkin and a-
Synuclein. Both human a-Synuclein and T240R were
over-expressed (Figure 1D) but mutant parkin had no
effects on a-Synuclein levels. We also tested the expres-
sion levels of parkin and human a-Synuclein by immu-
nohistochemistry, and observed an increase in parkin
immunoreactivity in parkin (Figure 1F; Lv-Par), and par-
kin+a-Synuclein (Figure 1H; Lv-Par+Lv-Syn) injected
brains compared to LacZ (Figure 1E; Lv-LacZ) and a-
Synuclein (Figure 1G, Lv-Syn) injected brains. We then
used a human anti-a-Synuclein antibody to examine the
expression level of lentiviral a-Synuclein. No expression
of human a-Synuclein was observed in LacZ (Figure 1I)
and parkin expressing brains (Figure 1J). Injection of
lentiviral a-Synuclein caused cellular accumulation of
human a-Synuclein (Figure 1K), but this accumulation
was reduced with parkin co-expression (Figure 1L).
These data suggest that parkin reduces the expression
levels of a-Synuclein.
The effects of lentiviral parkin expression on a-Synuclein-
induced cell death in gene transfer animal models
To examine whether the lentivirus, a-Synuclein or par-
kin cause cell death in these animal models, we used sil-
ver staining to detect cell death and degeneration
in vivo. Injection of lentiviral LacZ into the striatum did
not result in detectable positive silver staining (Figure
2A) indicating that the lentivirus does not cause cell
death in our control animals. No silver-positive cells
were detected in the parkin injected striatum (Figure
2B), but silver-positive cells were observed when a-
Synuclein was expressed (Figure 2C, arrows). Morpholo-
gical changes were also observed in silver-positive (dark)
cells. Stereological counting demonstrated a significant
increase (32%, N = 4) in silver-positive cells in a-Synu-
clein injected striatum (Figure 2C) compared to LacZ
injection (Figure 2A). Co-expression of parkin and
a-Synuclein showed fewer (13% decrease of control,
N = 4) silver-stained cells (Figure 2D) compared to a-
Synuclein expression alone (Figure 2C). We performed
tyrosine hydroxylase (TH) staining to examine whether
cell death in striatal neurons was accompanied by loss
of dopaminergic nerve terminals. TH staining revealed
no noticeable differences between LacZ (Figure 2E), par-
kin (Figure 2F), a-Synuclein (Figure 2G) and parkin+a-
Synuclein (Figure 2H) injected brains. Optical density
measurements of TH-positive staining of dopaminergic
terminals in the striatum did not show a statistically
significant (16% decrease) difference between
a-Synuclein injected brains and LacZ, parkin or parkin
+a-Synuclein injected brains, suggesting no loss of
dopaminergic nerve terminals in the striatum.
Further examination of the SN revealed no significant
changes in silver staining between the different treat-
ments (Figure 1I-L), indicating no degenerative loss of
neurons in SN. Further analysis with TH staining of
dopamine neurons in SN also showed no noticeable dif-
ferences between a-Synuclein (Figure 2O) injected
brains and LacZ (Figure 2M), parkin (Figure 2N) and
parkin+a-Synuclein (Figure 2P).
To further test the effects of parkin and a-Synuclein
expression of neuronal cell death, we performed cas-
pase-3 activity assays in striatal brain extracts and
observed a significant increase (34%, N = 4) in caspase-3
activity in a-Synuclein (Figure 2Q) expressing brains
compared to LacZ or parkin. Parkin expression reduced
caspase-3 activity back towards control level, suggesting
that parkin may protect against a-Synuclein-induced
activation of caspase-3.
Parkin expression reduces a-Synuclein-induced
inflammation
To test whether a-Synuclein expression induces inflam-
mation in our animal model, we examined signs of glial
activation. No noticeable differences in the morphology
or number of microglia were detected with IBA-1
immunostaining (Figure 3A-D). Injection with lentiviral
LacZ does not result in any changes to either microglial
(Figure 3A) or astrocytic (Figure 3E) morphology or
number. Astrocyte staining with glial fibrillary acidic
protein (GFAP) showed a marked change in cell mor-
phology (Figure 3G) and a significant increase (~190%,
N = 4) in glial number (P < 0.05) in a-Synuclein brains
(Figure 3G &3I) compared to LacZ (Figure 3E &3I) and
parkin injected brains (Figure 3F &3I). Parkin co-expres-
sion with a-Synuclein significantly reversed the effects
of a-Synuclein on astrocyte number (~50%, N = 4) and
morphology, but not to control level (Figure 3H &3I).
Further assessment of inflammatory molecules by
Western blot revealed a significant increase in TNF-a
(~100%, N = 4) and iNOS (71%) in the ipsilateral stria-
tum (P < 0.05) in a-Synuclein injected brains compared
to LacZ or parkin injected brains (Figure 3J &3K). Par-
kin partially reversed the effects (~20% increase) of a-
Synuclein on TNF-a levels (Figure 3J &3K), and signifi-
cantly (P < 0.05) reduced the a-Synuclein effects on
iNOS (40%, N = 4). These data demonstrate that a-
Synuclein causes inflammation in the rat striatum and
parkin expression reverses these inflammatory reactions,
consistent with the effects of parkin on neuronal
degeneration.
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Page 5 of 13Figure 2 a-Synuclein-induced cell death and parkin protection in gene transfer animal models. Silver staining in sections of rat striatum
injected with A). lentiviral LacZ, B). lentiviral parkin and C). lentiviral a-Synuclein (arrows indicate silver-positive cells) and D). lentiviral parkin+a-
Synuclein. Sections of rat striatum stained with TH antibody in lentiviral lacZ (Figure 2E), parkin (Figure 2F), a-Synuclein (Figure 2G) and parkin
+a-Synuclein (Figure 2H) injected brains. Silver staining in 20 micron thick sections of rat SN from brains injected with I). lentiviral LacZ, J) parkin,
K). a-Synuclein and L). parkin+a-Synuclein. TH staining of SN neurons from brains injected with M). lentiviral LacZ, N) parkin, O). a-Synuclein and
P). parkin+a-Synuclein. Q). Histogram represents caspase-3 activity assay. Asterisk is significantly different to LacZ control, ANOVA, with Neumann
Keuls multiple comparison N = 4, P < 0.05.
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Page 6 of 13Figure 3 a-Synuclein-induced neuro-inflammation and parkin protection. Immunostaining with microglia IBA-1 antibody in 20 micron thick
striatal sections of rat brains injected with A). lentiviral LacZ (Lv-LacZ), B). parkin (Lv-Par), C). a-Synuclein (Lv-Syn) and D). Lentiviral parkin+a-
Synuclein (Lv-Par+Lv-Syn). Immunostaining with astrocytic GFAP in rat striatum injected with E). lentiviral LacZ, F). parkin, G). a-Synuclein and H).
Lentiviral parkin+a-Synuclein I). Histograms represent stereological counting of IBA-1 and GFAP positive cells. J). Western blot of TNF-a and iNOS
in striatal extracts analyzed on 10% NuPAGE SDS gel (Invitrogen) and I). Densitometric analysis of immunoblots, Asterisk is significantly different
to LacZ control or as indicated, ANOVA, with Neumann Keuls multiple comparison N = 4, P < 0.05.
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modification of endogenous Tau
To test the effects of lentiviral gene delivery on kinases
and Tau phosphorylation, striatal extracts were analyzed
using Western blot 4 weeks post-injection. Human a-
Synuclein resulted in a significant increase in phospho-
GSK-3b (100%, ANOVA, P < 0.05, N = 4), indicating an
increase in the kinase activity in a-Synuclein injected
brains (Figure 4A &4B). However, human parkin com-
pletely reversed the effects of a-Synuclein on GSK-3b
activation back to LacZ (control) levels in the rat brain.
Neither parkin nor LacZ nor a-Synuclein had any
effects on AKT activation (data not shown). To examine
changes in Tau phosphorylation, we probed for different
Tau epitopes (Figure 4). No changes in the levels of
total Tau or Tau phosphorylation at Ser 262 and Thr
181 (Figure 4C) were observed. However, significant
increases (ANOVA, P < 0.05, N = 4) were detected on
other Tau phosphorylation sites, including Ser 396
(34%), Ser 202/Thr 205 (38%, N = 4) and Thr 231 (19%,
N=4 )i na-Synuclein injected brains (Figure 4C &4D).
Parkin significantly reversed the effects of a-Synuclein
on Ser 202/Thr 205 and Thr 231 and Ser 396 (Figure
4C &4D) back to LacZ levels. These data indicate that
a-Synuclein over-expression increases GSK-3b activity
and endogenous Tau hyper-phosphorylation and parkin
reverses these effects.
Parkin decreases a-Synuclein phosphorylation
To study the effects of parkin on a-Synuclein phosphor-
ylation, we expressed parkin in doxycycline-inducible a-
Synuclein MN9 D cells. Lentiviral parkin expression
resulted in a significant (50%, N = 12) increase in parkin
level (Figure 5A) compared to non-transfected cells.
Fractionation of total a-Synuclein into phosphorylated
(p-a-Syn) and non-phosphorylated a-Synuclein (non-
p-a-Syn) showed a significant increase of p-a-Synuclein
expression levels in +Dox cells (Figure 5A) compared to
-Dox cells. The level of non-p-a-Synuclein in -Dox cells
was undetectable by Western blot. Cells expressing par-
kin demonstrated a significant decrease (30%, N = 12)
in p-a-Synuclein (Figure 5A), and no change in the level
of non-p-a-Synuclein (Figure 5A), suggesting that the
change in total a-Synuclein levels may be due to
changes in phosphorylated a-Synuclein fraction.
We then tested whether parkin affects a-Synuclein
phosphorylation in vivo. Striatal extracts of lentiviral par-
kin and/or a-Synuclein injected brains were analyzed 4
weeks post-injection, with parkin and a-Synuclein antibo-
dies. No difference in p-Ser 129 was detected between
LacZ and parkin injected brains (Figure 5B &5C). The
ratio of p-Ser 129/total a-Synuclein (p-Ser129/Syn) was
significantly (72%, N = 4) increased (P < 0.05) (Figure 5B
&5C), and higher molecular weight species (~49 Kd) were
observed in the a-Synuclein injected brains. Co-expression
of parkin and a-Synuclein resulted in a significant
decrease (P < 0.05, N = 4) in the ratio of p-Ser129/Syn
(32%, N = 4) and a decrease in the levels of higher molecu-
lar weight species. Endogenous p-Ser 87 was not detected
in the parkin expressing rat brain (Figure 5B), but p-Ser
87/Syn was significantly elevated (2350-fold, N = 4) in
brains injected with human a-Synuclein. Parkin signifi-
cantly reduced the level of p-Ser 87 (Figure 5B &5D) when
it was co-expressed with a-Synuclein. A higher molecular
weight size band (~49 Kd) was observed in brains expres-
sing human a-Synuclein when probed with the p-Ser 87
antibody (Figure 5B). These data indicate that parkin over-
expression protects against a-Synuclein-induced pathol-
ogy and reduces the levels of human p-Ser 87 and p-Ser
129 in vivo. We further tested the levels of Polo-Like-
Kinase-2 (PLK2), which is known to phosphorylate
a-Synuclein at Serine-129 and we found that PLK2 levels
were significantly increased (54%, N = 4, P < 0.05) in
a-Synuclein injected brains compared to LacZ or parkin
levels (Figure 5B &5E). Co-expression of parkin and
a-Synuclein resulted in reduction of PLK2 levels.
Detection of phosphorylated a-Synuclein and
decreased phosphorylation in the presence of parkin led
us to examine protein phosphatases that may be
involved in protein de-phosphorylation. No changes
were observed with protein phosphatase-1 (data not
shown) or the levels of the scaffolding subunit A (Figure
5F &5G) of protein phosphatase-2A (PP2A), in the pre-
sence or absence of either a-Synuclein or parkin or
LacZ. Further examination of other sub-units of PP2A
showed that parkin caused a significant (P < 0.05, N =
4) increase (~60%) in the protein levels of both the reg-
ulatory subunit B (PP2A-B) and the catalytic subunit C
(PP2A-C) compared to a-Synuclein expression and
LacZ (Figure 5F &5G). To verify that parkin mediates
the decrease in a-Synuclein levels via PP2A, we inhib-
ited PP2A with the classical inhibitor okadaic acid (OA)
in the presence of parkin (Figure 5H). PP2A inhibition
with OA prevented parkin from decreasing a-synuclein
levels (Figure 1H, N = 6). These data indicate that par-
kin expression may specifically lead to changes in a-
Synuclein de-phosphorylation via its effects on PP2A
levels in MN9 D cells. To further test whether these
effects are mediated by parkin expression, we expressed
T240R mutant parkin (Figure 1I) and observed no dif-
ference in the level of a-Synuclein or PP2A levels, sug-
gesting that parkin may mediate the phosphorylation of
a-Synuclein via its effects on PP2A.
The increase in PP2A-B and C protein levels led to the
examination of phosphatase activity in these animal mod-
els. Lentiviral parkin expression significantly increased
(~60%, N = 4) phosphatase activity in parkin or parkin+a-
Synuclein (Figure 5J) injected animals, compared to LacZ
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cate that phosphatases, including PP2A and kinases, such
as PLK2, may be involved in the modulation of a-Synu-
clein phosphorylation and parkin can activate PP2A,
which may affect protein de-phosphorylation.
Discussion
We generated gene transfer animal models and studied
the effects of parkin on post-translational modifications
of wild type a-Synuclein and examined the interaction
between these two proteins. a-Synuclein expression
caused cell death and increased PLK2 levels leading to
a-Synuclein phosphorylation [18,35]. a-Synuclein
expression increased GSK-3b activity and Tau phos-
phorylation. Parkin expression was associated with an
increase in phosphatase activity. Parkin expression
decreased the levels of PLK2 and phosphorylated a-
Synuclein; and decreased GSK-3b activity and the
Figure 4 a-Synuclein-induced activation of GSK-3b and Tau hyper-phosphorylation and parkin protection. A). Western blot analysis of
striatal brain extracts on Nu-PAGE SDS 10% gel (Invitrogen) and B). Densitometry analysis showing GSK-3b activity. C). Western blot analysis
showing different Tau epitopes and. B) densitometric analysis of immunoblots, Asterisk is significantly different, ANOVA, with Neumann Keuls
multiple comparison N = 4, P < 0.05.
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Page 9 of 13Figure 5 Parkin expression prevents a-Synuclein phosphorylation and increases phosphatase activity. A). WB of fractionated a-Synuclein
from a-Synuclein stably transfected MN9 D cells and infected with lentiviral parkin and B). WB analysis of striatal brain extracts using 4-12%
NuPAGE SDS gel (Invitrogen) probed with various a-Synuclein antibodies and PLK2 antibody. C, D&E). Densitometry of blots expressed as %
control. F). WB analysis of protein phosphatase-2A subunits from striatal brain extracts and. G). Densitometry of blots expressed as % control. H).
WB of a-Synuclein stably transfected MN9 D cells infected with lentiviral parkin and treated with PP2A inhibitor okadaic acid, and I) WB of T240R
mutant and PP2A subunits. J). Phosphatase activity assay. Asterisk is significantly different, ANOVA with Neumann Keuls multiple comparison N =
4 for animals, N = 6 for MN9 D cells, P < 0.05.
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a-Synuclein over-expression increases kinase activity
and leads to Tau and a-Synuclein phosphorylation,
while parkin increases phosphatase activity to de-
phosphorylate proteins and counteract the effects of a-
Synuclein over-expression. While the effects of parkin on
a-Synuclein are consistent with previous studies in mutant
A30P a-Synuclein injected rats,w h i c hs h o wt h a tp a r k i n
reverses the effects of a-Synuclein on cell death [25], we
further tested the role of parkin in post-translational mod-
ification of a-Synuclein, Tau phosphorylation and inflam-
mation in the present models. The gene transfer animal
model we developed demonstrates the pathological effects
of wild type a-Synuclein. Lentiviral infection resulted in
an increase in a-Synuclein levels in the striatum, within
t h ep a t h o l o g i c a lr a n g eo fi n c r e a s ei nP D ,i nw h i c ho v e r -
expression of a-Synuclein is associated with disease patho-
genesis [36-38]. Expression of a-Synuclein resulted in cell
death [25,39,40]. Inflammatory signs were observed in this
a-Synuclein model and parkin protected against changes
in astroglial morphology and inflammatory molecules,
providing evidence of a-Synuclein-induced pathology and
parkin suppression of a-Synuclein effects on inflamma-
tion. However, microglial activation may depend on a spe-
cific time course and localization of protein expression.
Intracellular accumulation of a-Synuclein within the stria-
tum might induce a different immune response compared
to other brain regions [i.e. SN]. These results are consis-
tent with previous data showing that parkin deficiency in
mice increases the risk of inflammation and neuronal
death [41].
Parkin expression results in a-Synuclein de-phosphor-
ylation at Ser 87 and Ser 129 and attenuates the phos-
phorylation of Tau at several Ser and Thr residues.
These findings are intriguing and suggest new mechan-
isms of a-Synuclein effects and parkin role in modulat-
ing phosphatase activity and its ability to recruit cellular
substrates. The PP2A core enzyme comprises a scaffold-
ing subunit A, a catalytic subunit B and a regulatory
subunit C [42,43]. To gain activity toward specific sub-
strates, PP2A-A interacts with variable regulatory B sub-
units to form a heteromeric holoenzyme [42,43].
Changes in phosphatase activity led to the examination
of the relationship between a-Synuclein expression and
endogenous Tau phosphorylation. Activation of the reg-
ulatory subunit PP2A-B mediates Tau dephosphoryla-
tion [44]. PP2A specifically targets Ser and Thr residues,
resulting in protein de-phosphorylation [42,44]. The
effects of parkin on PP2A and the decrease in phos-
phorylated a-Synuclein levels may explain the protective
effects of parkin. However, it is not understood how
parkin might affect PP2A activity or levels, we did not
observe any direct interaction between the two proteins
with co-immunoprecipitation (data not shown), and
there are no previous reports to discuss any relationship
between parkin and phosphatases. The association
between parkin expression and decreased Tau and a-
Synuclein phosphorylation is intriguing, and suggests
that parkin may protect against a-Synuclein-induced
cell death by maintaining a stoichiometric balance
between phosphorylated and non-phosphorylated pools
of proteins.
Modification of a-Synuclein at Ser 129 may trigger a-
Synuclein pathology in dopaminergic cells, but only a
fraction of a-Synuclein is phosphorylated [15]. p-Ser
129 appears to be the major phosphorylated form of a-
S y n u c l e i ni nL Bi n c l u s i o n s[ 3 1 ,32]. Ubiquitinated p-Ser
129 increases in parkin-deficient mice [45] and
increased levels of p-Ser 129 leads to protection of
dopaminergic neurons in the presence of parkin [25].
However, we found that parkin decreased the levels of
p-Ser 129 in vivo, and decreased the levels of higher
molecular weight species (with no evidence of either
ubiquitination or LB formation), suggesting that parkin
expression may lead to a decrease in a-Synuclein level,
primarily via reduction of its phosphorylated fraction.
The data suggest that neither endogenous nor over-
expressed parkin affects the native and p-Ser 129 levels
of rat a-Synuclein [45,46], and the decrease in p-Ser
129 is only observed when human a-Synuclein is
expressed. In cellular models of Synucleinopathies, ubi-
quitinated inclusions increase when human a-Synuclein
is co-expressed with parkin and synphilin-1, but
decrease when phosphorylation of a-Synuclein is
blocked by expression of the S129A a-Synuclein mutant
[33]. Taken together, the data suggest that phosphoryla-
tion may be an early cellular coping mechanism in
Synucleinopathies, whereas ubiquitination of phosphory-
lated a-Synuclein is a later process involving possible
sequestration and protein clearance.
p-Ser 87 is found in cell lines [11] and recent findings
by Lashuel and coworkers demonstrated that p-Ser 87
co-localizes with a-Synuclein in LBs and is elevated in
diseased brains [47]. The absence of p-Ser 87 from the
rat brain suggests that this phosphorylated form is
derived from expression of human a-Synuclein. Ser 87
lies within the hydrophobic non-amyloid component
[48] region of a-Synuclein, and is one of the residues
that distinguish the human a-Synuclein sequence from
its mouse and rat homologs, suggesting that this residue
may contribute to the differential modification of
human and rat a-Synuclein. Moreover, a-Synuclein
phosphorylation, particularly within the NAC domain
(71-82) that promotes aggregation [49,50] and the C-ter-
minus (120-140) that decreases aggregation [49], may
alter the properties of a-Synuclein depending on the
phosphorylation state of either Ser 87 or Ser 129.
Further studies are required to determine if there is a
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Synuclein.
Conclusions
Taken together, these studies provide evidence that wild
type human a-Synuclein is pathological and can be
phosphorylated in vivo to result in protein aggregation.
Parkin decreases GSK-3b activity and reduces Tau phos-
phorylation, inflammation and cell death. Phosphoryla-
tion of a-Synuclein in PD and other Synucleinopathies
may be mitigated by the effects of PP2A. In this animal
model, parkin protects against a-Synuclein-induced
pathology by increasing phosphatase activity and
decreasing PLK2 levels to attenuate the levels of aggre-
gation-prone p-Ser-129 and p-Ser 87. Parkin expression
may be used as a potential therapeutic strategy to coun-
teract the effects of a-Synuclein toxicity in the
Synucleinopathies.
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